Sichuan Elixir Pharmaceuticals Ursodeoxycholic Acid Sichuan Elixir Pharmaceuticals Ursodeoxycholic Acid

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find PharmaFlow Article for Prestwick3_000958

    Client Email Product

    Prestwick3_000958

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    67
    US DMFs Filed

    US DMFs Filed

    21
    CEP/COS Certifications

    CEP/COS Certifications

    20
    JDMFs Filed

    JDMFs Filed

    12
    Other Certificates

    Other Certificates

    3
    Other Suppliers

    Other Suppliers

    35
    API REF. PRICE (USD / KG)
    314

    API Market Place

    24
    INTERMEDIATES
    2
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    32
    Europe

    Europe

    84
    Canada

    Canada

    12
    Australia

    Australia

    5
    South Africa

    South Africa

    2
    Uploaded Dossiers

    Uploaded Dossiers

    38
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    965.00

    Annual Reports

    52.00

    FDF Market Place

    12
    EXCIPIENTS
    237
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    39
    REF STANDARD

    EDQM

    4

    USP

    1

    JP

    0

    Other Listed Suppliers

    6
    SERVICES
    1
    left grey arrow
    right gray arrow
    • CAPSULE;ORAL - 300MG
    • TABLET;ORAL - 250MG
    • TABLET;ORAL - 500MG
    BlogBlog
    Full View ScreenFull Screen View
    Move over Statins, Sartans, Tinibs; it’s time for “Cholic chemistry”

    Move over Statins, Sartans, Tinibs; it’s time for “Cholic chemistry”

    Recently, FDA approved therapies to reduce double chin (yes it’s possible!) and treat patients with bile acid synthesis disorders through compounds derived from bile acids. Bile, that bitter, alkaline liquid secreted by livers, has formed the base for producing Cholic Acid and Deoxycholic Acid, which led to the recent approvals: Kythera Pharamceutical’s ATX-101 (Deoxycholic Acid, DCA) injection for submental fat (double chin) and AskLepion’s CHOLBAM (Cholic Acid, CA) capsules for the treatment of bile acid synthesis due to single enzyme defects. Kythera modified the age old French practice of mesotherapy (non-surgical cosmetic medicine treatment), where the combination of deoxycholic acid and phosphatidylcholine is used to reduce fat by demonstrating that dexoxycholic acid alone can get the job done. While the combination is used in mesotherapy, studies have demonstrated that phosphatidylcholine has a limited role in fat reduction, so Kythera’s science doesn’t exactly qualify as revolutionary.  Kythera’s ability to navigate the complex regulatory landscape (they won a unanimous approval 17-0 from the FDA Advisory Committee) seems well worth it as ATX-101’s sales potential of $300 million makes Kythera a potential takeover target for larger pharmaceutical companies. The two approvals is a resurgence for bile acid salts since Cholic Acid has been used for decades to produce Ursodiol (Ursodeoxycholic Acid), a treatment for gallstones with pharma majors like Sanofi and Roche having manufactured the active ingredient in the past.  There is more to come in the story of bile acid salts as they form the base for breakthrough treatments for Nonalcoholic Steatohepatitis (NASH) - a serious chronic liver disease which can lead to cirrhosis, eventual liver failure and death.   There are currently no drugs approved for the treatment of NASH and recent epidemiological studies estimate that more than 10% of the U.S. adult population has NASH, with more than 60% of patients (potentially more than 14 million in total) have liver fibrosis, or cirrhosis, due to progression of the disease. Intercept Pharmaceuticals, with its modified bile acid Obeticholic Acid (OCA), has been assigned Breakthrough Therapy status by the FDA. The effectiveness of Obeticholic Acid and size of the patient population explains why Intercept has been a darling of the stock market through 2014, especially as the product is expected to gain approval later this year. Expected sales estimates of the potential blockbuster range between $2-4 billion and explain the $6 billion stock market valuation. Further upstream, Israel based, Galmed Pharmaceuticals has a compound in Phase IIb clinical trials which couples Cholic Acid with the commonly available fatty acid, Arachidic Acid for the same indication as Obeticholic Acid. After Gilead’s recent purchase of Phenex Pharmaceuticals for $470 million to get access to their NASH compound, the potential upside of NASH compounds is HUGE! We already have established molecule classes like Statins, Sartans & Tinibs, maybe it’s time to get work started on "Cholic chemistry”! Search our database for Cholic Acid and Deoxycholic Acid to find suppliers, pricing information and a lot more…  

    Impressions: 5613

    subscribeSubscribe
    ExcelExcel Download

    https://www.pharmacompass.com/radio-compass-blog/move-over-statins-sartans-tinibs-it-s-time-for-cholic-chemistry

    #Phispers by PHARMACOMPASS
    26 Mar 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Axplora Ursodeoxycholic Acid

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Ursodeoxycholic Acid RMB

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search